ITD 1

Drug Profile

ITD 1

Alternative Names: ITD-1

Latest Information Update: 01 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemRegen; Human BioMolecular Research Institute; Sanford Burnham Prebys Medical Discovery Institute
  • Class Heart failure therapies; Stem cell therapies
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Heart failure

Highest Development Phases

  • Preclinical Heart failure

Most Recent Events

  • 01 Aug 2016 ITD 1 is available for licensing as of 01 Aug 2016. http://chemregen.com/
  • 01 Aug 2016 Preclinical trials in Heart failure in USA prior to this date (Parenteral or PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top